Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in⦠(NCT06955858) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia
China60 participantsStarted 2025-05-30
Plain-language summary
Evaluation of the efficacy and safety of recombinant human thrombopoietin (rhTPO) at 300 U/kg/day for hematopoietic stem cell mobilization in autologous transplantation among acute leukemia patients
Who can participate
Age range18 Years β 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
β. Age 18ο½65 years, regardless of gender.
β. Histopathologically confirmed acute leukemia with immunohistochemical validation
β. Eastern Cooperative Oncology Group (ECOG) performance status smaller than 2 and a life expectancy of more than 6 months
β. No active infectious disease; no severe organ failure.
β. Willingness to participate with written informed consent for study enrollment.
Exclusion criteria
β. Liver dysfunction (alanine aminotransferase or bilirubin greater than two times the normal upper limit).
β. Renal dysfunction (creatinine or urea higher than 1.5 times the normal upper limit).
β. Any disease that could put patients at high risk, including but not limited to unstable cardiac disease, uncontrolled atrial fibrillation or hypertension, severe diabetic retinopathy
β. rhTPO aller- gies.
β. Severe prior thrombosis-event.
β. History of other malignancy, unless cured for more than 3 years
β. Pregnant or lactating women
What they're measuring
1
total CD34+ cell count
Timeframe: two weeks
Trial details
NCT IDNCT06955858
SponsorInstitute of Hematology & Blood Diseases Hospital, China